Bevacizumab-awwb 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Bevacizumab-bvzr 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
The systemic safety of bevacizumab appears to be similar to that of ranibizumab as intravitreal therapy for neovascular age-related macular degeneration (AMD).
The addition of bevacizumab to carboplatin and paclitaxel chemotherapy for the first-line treatment of women with ovarian cancer may offer benefit compared with standard chemotherapy alone, particularly for patients with more aggressive disease, investigators noted in a presentation during the American Society of Clinical Oncology's 2011 Annual Meeting.
Adjuvant bevacizumab increases overall survival in cervical cancer and improves progression-free survival in glioblastoma.
For women with ovarian cancer, the addition of bevacizumab to standard chemotherapy results in significantly improved progression-free survival (PFS).
Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who have progressed after discontinuation of first-line bevacizumab and chemotherapy.
Ophthalmic injections of bevacizumab exhibited no greater risk of endophthalmitis than injections of ranibizumab, according to a new study published in JAMA Ophthalmology.
The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.